Kazakos Evangelos I, Petinaki Efthymia, Liatsos Christos, Papanikolaou Ioannis S, Anastasiadou Kyriaki, Kountouras Jannis
Department of Microbiology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa University Hospital, 41110 Larissa, Greece.
Department of Medicine, Second Medical Clinic, Aristotle University of Thessaloniki, Ippokration Hospital, 54642 Thessaloniki, Greece.
Microorganisms. 2025 Aug 12;13(8):1883. doi: 10.3390/microorganisms13081883.
(), a widespread gastric pathogen, has long been studied for its role in upper gastrointestinal disorders. While its involvement in gastritis, peptic ulcer disease, and gastric cancer is well established, its impact on esophageal diseases remains an area of ongoing investigation. Nevertheless, some data indicate that may be involved in the pathogenesis of gastroesophageal reflux disease-Barrett's esophagus-esophageal adenocarcinoma sequence. Similarly, the -related mast cell activation-an essential immunological event-may also play a crucial role in the progression from gastroesophageal reflux disease to Barrett's esophagus and esophageal adenocarcinoma. The underlying mechanisms include immune modulation, cytokine cascades, and microbial interactions that collectively shape the esophageal microenvironment. This review provides an in-depth analysis of these pathways, highlighting the potential role of -induced, mast cell-driven inflammation in esophageal disease progression and discussing emerging therapeutic strategies.
()是一种广泛存在的胃部病原体,长期以来一直在研究其在上消化道疾病中的作用。虽然其在胃炎、消化性溃疡病和胃癌中的作用已得到充分证实,但其对食管疾病的影响仍是一个正在研究的领域。然而,一些数据表明,()可能参与了胃食管反流病-巴雷特食管-食管腺癌序列的发病机制。同样,与()相关的肥大细胞活化——一个重要的免疫事件——也可能在从胃食管反流病进展为巴雷特食管和食管腺癌的过程中起关键作用。潜在机制包括免疫调节、细胞因子级联反应和微生物相互作用,这些共同塑造了食管微环境。本综述对这些途径进行了深入分析,强调了()诱导的、肥大细胞驱动的炎症在食管疾病进展中的潜在作用,并讨论了新出现的治疗策略。
需注意,原文中括号处内容缺失,以上译文是在假设括号内无具体内容的情况下进行的常规翻译。
Visc Med. 2024-10
Minerva Gastroenterol (Torino). 2024-12
Wien Klin Wochenschr. 2025-7-25
Cochrane Database Syst Rev. 2010-1-20
Curr Opin Gastroenterol. 2013-7
J Gastroenterol Hepatol. 2025-7-15
Pharmacol Ther. 2025-5-30
Front Biosci (Landmark Ed). 2025-3-18
Front Microbiol. 2025-2-27